UK-based digital health company Numan has secured $60 million in funding to expand its preventative health platform, including the introduction of a new hormonal health offering for women’s health. The company, which has primarily focused on men’s health services, is broadening its reach as it continues its mission to make proactive, patient-centered care more accessible.
The funding round included participation from long-term investors White Star Capital and Novator, alongside new investors Big Pi Ventures, Endeavor Catalyst, and HSBC Innovation Banking. Numan has treated over 650,000 patients to date and achieved its first year of profitability in 2024, with revenue more than doubling to over $90 million.
Founded seven years ago, Numan has built a platform that combines diagnostics, medication, expert care, and behavioral support into personalized health journeys spanning prevention and treatment. The company is now expanding beyond its core men’s health services to include women’s hormonal health as part of its broader healthcare evolution.
“Post-Covid, we’ve also seen the rise of a more empowered, proactive patient – eager to understand their health and take control,” said Sokratis Papafloratos, CEO of Numan. “Historically, achieving optimal health has been expensive, time-consuming, and inaccessible. But today, we’re at a pivotal moment: the convergence of technology, clinical evidence, and cultural readiness gives us a unique chance to reshape healthcare.”
The women’s health expansion represents a significant strategic shift for Numan, which has established itself in the men’s health market through services addressing conditions like erectile dysfunction, hair loss, and testosterone optimization. The move into women’s hormonal health reflects growing demand for comprehensive digital health solutions that address gender-specific healthcare needs.
Numan has developed an AI-powered health coach that the company says sets new standards for safety, efficacy, and scalability while delivering significant benefits for patients. The platform approach integrates multiple healthcare touchpoints to provide holistic care rather than isolated treatments.
The funding will support Numan’s mission to address major health challenges including obesity, diabetes, cancer, and mental health through proactive, technology-enabled interventions. The company has specifically stated its goal to “end obesity,” targeting a condition that costs the UK over £126 billion annually.
For women’s health specifically, the hormonal health offering could address gaps in accessible care for conditions related to menopause, reproductive health, and hormone optimization. The expansion positions Numan to serve both men and women through its integrated digital health platform.
